Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
mezagitamab (TAK-079)
i
Other names:
TAK-079, TAK079, TAK 079
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Twitter
Trials
Company:
Takeda
Drug class:
CD38 inhibitor
Related drugs:
‹
daratumumab (26)
isatuximab-irfc (12)
daratumumab/hyaluronidase (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
SAR442085 (1)
SAR442257 (1)
MOR202 (1)
daratumumab (26)
isatuximab-irfc (12)
daratumumab/hyaluronidase (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
SAR442085 (1)
SAR442257 (1)
MOR202 (1)
›
Associations
(1)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
CD38 expression
Multiple Myeloma
CD38 expression
Multiple Myeloma
TAK-079
Sensitive: D – Preclinical
TAK-079
Sensitive
:
D
TAK-079
Sensitive: D – Preclinical
TAK-079
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login